Structure and computation-guided design of a mutation-integrated trimeric RBD candidate vaccine with broad neutralization against SARS-CoV-2

Yu Liang, Jing Zhang, Run Yu Yuan, Mei Yu Wang, Peng He, Ji Guo Su, Zi Bo Han, Yu Jin, Jun Hou, Hao Zhang, Xuefeng Zhang, Shuai Shao, Ya Nan Hou, Zhao Ming Liu, Li Fang Du, Fu Jie Shen, Wei Min Zhou, Fang Tang, Ze Hua Lei, Shuo Liu, Zhen Wei, Jin Juan Wu, Xiang Zheng, Ning Liu, Shi Chen, Zhi Jing, Fan Zheng, Si Yu Ren, Zhong Hu, Gui Zhen Wu, Weijin Huang, Ke Chang, Qi Ming LibioRxiv 2021 · DOI

TL;DR

This paper introduces a novel, multi-strain SARS-CoV-2 vaccine candidate, "mutI tri-RBD," designed using structural and computational methods. This vaccine integrates receptor-binding domains (RBDs) from three different SARS-CoV-2 variants into a single trimeric structure, demonstrating superior broad neutralization against various viral strains, including immune-evasive ones, compared to a single-strain vaccine.

What Problem Does This Paper Address?

The rapid evolution of SARS-CoV-2 has led to the emergence of numerous variants, some of which exhibit "immune escape" properties. This means that antibodies generated by natural infection or vaccination against earlier strains may be less effective against these new variants, posing a significant challenge to existing vaccines and public health efforts. The authors aim to address this by developing a vaccine that can elicit a broad neutralizing antibody response capable of targeting multiple SARS-CoV-2 variants, thus providing more robust and durable protection.

Methods

The researchers employed a structure-guided and computation-driven approach to design their vaccine candidate. Key methods included:

  • Structural Modeling and Molecular Dynamics (MD) Simulations: They used the native structure of the SARS-CoV-2 spike protein trimer as a template to design a trimeric RBD structure. MD simulations were used to assess the stability and intrinsic dynamics of the designed structures.
  • Recombinant Protein Expression and Purification: The mutI tri-RBD and a control homo-tri-RBD (composed of only the prototype strain's RBD) were expressed in mammalian HEK293T cells and purified.
  • Biochemical Characterization: Techniques like MALDI-TOF MS, Circular Dichroism (CD) spectroscopy, Differential Scanning Calorimetry (DSC), Surface Plasmon Resonance (SPR), and ELISA were used to confirm protein folding, stability, bio-activity, and binding affinity to the host cell receptor (hACE2) and neutralizing antibodies.
  • Immunization Studies in Mice: BALB/c mice were immunized with the mutI tri-RBD and homo-tri-RBD, with and without aluminum adjuvant, using various immunization regimens and doses.
  • Serological Assays: ELISA was used to measure RBD-specific IgG titers. Pseudo- and live-virus neutralization assays were conducted to evaluate the neutralizing antibody titers against various SARS-CoV-2 strains.

Datasets

The study utilized sequences from circulating SARS-CoV-2 strains, specifically the prototype strain, Beta (B.1.351), and Kappa (B.1.617.1), to construct the mutI tri-RBD. For neutralization assays, 22 different SARS-CoV-2 pseudo-viruses representing various circulating strains and single/combinatorial mutations were used. The study also used live SARS-CoV-2 prototype and Beta (B.1.351) strains for neutralization assays.

Key Insights and Ideas

  • Trimeric RBD Mimicry: The researchers hypothesized that mimicking the natural trimeric arrangement of RBDs in the spike protein would enhance immunogenicity.
  • Multi-Strain Integration: By grafting RBDs from different circulating strains into a single trimeric structure, they aimed to create a "one-stop shop" for eliciting broad immunity.
  • "Immune Escape" Variant Targeting: The inclusion of RBDs from variants like Beta (B.1.351), known for immune escape, was a strategic choice to specifically challenge and improve neutralization against these difficult strains.
  • Computational Design for Vaccine Development: The study highlights the power of combining structural biology and computational modeling to rationally design novel vaccine candidates with improved efficacy.

Key Results

  • Successful Production and Characterization: The mutI tri-RBD and homo-tri-RBD proteins were successfully expressed, folded correctly, and demonstrated high stability and bio-activity.
  • Robust Immune Response Against Prototype: Both mutI tri-RBD and homo-tri-RBD induced high levels of specific IgG and neutralizing antibodies against the SARS-CoV-2 prototype strain in mice.
  • Superior Neutralization of Beta Variant: Notably, the mutI tri-RBD elicited significantly higher neutralizing antibody titers against the Beta (B.1.351) variant compared to the homo-tri-RBD.
  • Broad Neutralization Against Multiple Variants: The mutI tri-RBD demonstrated strong broadly neutralizing activities against a panel of 22 SARS-CoV-2 variants, including those that showed reduced sensitivity to antibodies generated by the homo-tri-RBD.
  • Potential for Future Variants: The inclusion of mutations known to confer immune resistance suggests that mutI tri-RBD may offer protection against future emerging SARS-CoV-2 variants.

Limitations and Future Work

  • Incomplete Variant Coverage: While the study tested a broad range of variants, the Kappa (B.1.617.1) pseudo- and live viruses were not available for direct testing. However, the authors speculate on its potential efficacy based on the mutations present.
  • Mouse Model: The study was conducted in mice, and further validation in human clinical trials is necessary to confirm efficacy and safety in humans.
  • Clinical Trial Status: While the homo-tri-RBD has been approved for clinical trials, the mutI tri-RBD, showing superior broad neutralization, is positioned as a more promising candidate for further clinical development. The authors suggest that its improved broad neutralization capabilities warrant its progression into clinical trials.

Summary updated

Abstract

Abstract The spike (S) protein receptor-binding domain (RBD) of SARS-CoV-2 is an attractive target for COVID-19 vaccine developments, which naturally exists in a trimeric form. Here, guided by structural and computational analyses, we present a mutation-integrated trimeric form of RBD (mutI tri-RBD) as a broadly protective vaccine candidate, in which three RBDs were individually grafted from three different circulating SARS-CoV-2 strains including the prototype, Beta (B.1.351) and Kappa (B.1.617). The three RBDs were then connected end-to-end and co-assembled to possibly mimic the native trimeric arrangements in the natural S protein trimer. The recombinant expression of the mutI tri-RBD, as well as the homo-tri-RBD where the three RBDs were all truncated from the prototype strain, by mammalian cell exhibited correct folding, strong bio-activities, and high stability. The immunization of both the mutI tri-RBD and homo-tri-RBD plus aluminum adjuvant induced high levels of specific IgG and neutralizing antibodies against the SARS-CoV-2 prototype strain in mice. Notably, regarding to the “immune-escape” Beta (B.1.351) variant, mutI tri-RBD elicited significantly higher neutralizing antibody titers than homo-tri-RBD. Furthermore, due to harboring the immune-resistant mutations as well as the evolutionarily convergent hotspots, the designed mutI tri-RBD also induced strong broadly neutralizing activities against various SARS-CoV-2 variants, especially the variants partially resistant to homo-tri-RBD. Homo-tri-RBD has been approved by the China National Medical Products Administration to enter clinical trial (No. NCT04869592 ), and the superior broad neutralization performances against SARS-CoV-2 support the mutI tri-RBD as a more promising vaccine candidate for further clinical developments.
BibTeX
@misc{liang2021structure,
  author = {Yu Liang and Jing Zhang and Run Yu Yuan and Mei Yu Wang and Peng He and Ji Guo Su and Zi Bo Han and Yu Jin and Jun Hou and Hao Zhang and Xuefeng Zhang and Shuai Shao and Ya Nan Hou and Zhao Ming Liu and Li Fang Du and Fu Jie Shen and Wei Min Zhou and Fang Tang and Ze Hua Lei and Shuo Liu and Zhen Wei and Jin Juan Wu and Xiang Zheng and Ning Liu and Shi Chen and Zhi Jing and Fan Zheng and Si Yu Ren and Zhong Hu and Gui Zhen Wu and Weijin Huang and Ke Chang and Qi Ming Li},
  title = {{Structure and computation-guided design of a mutation-integrated trimeric RBD candidate vaccine with broad neutralization against SARS-CoV-2}},
  year = {2021},
  doi = {10.1101/2021.06.18.448958},
  howpublished = {bioRxiv},
}
Figure